Presentation by Paul Brain, Project Manager at the Excel in Health series - Introduction to data webinar on Monday 6 June 2022.
In this session we discussed how SMEs can use data to grow their business and access new opportunities in the market.
Using Innovative Technology to Improve Medication Adherence. These slides were presented at Wessex Health Innovation Forum: Southampton on May 16th 2017.
Advanced health technologies and their budgetary implications - Valérie Paris...OECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th meeting of the joint OECD DELSA-GOV network on fiscal sustainability of health systems held in Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Valerie Paris, OECDOECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
20191203 DOE Data Driven Healthcare- Expert EventDayOne
DayOne Experts - Data-driven healthcare – are we ready?
Data is transforming healthcare. Health data from multiple sources such as electronic health records, genomic testing, imaging and digital tools, combined with advanced analytics can be used to deliver more personalised care, improve outcomes, empower patients and make healthcare more sustainable and efficient. But is the industry ready for these new approaches? What is needed on the policy level and in the regulatory field to enable a new era of data driven health solutions? How will their business models look like?
This is what we discussed at this DayOne Expert Event, which was proudly presented in close collaboration with the Embassy of the Netherlands, fostering the exchange between two world leading healthcare innovation ecosystems.
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
Using Innovative Technology to Improve Medication Adherence. These slides were presented at Wessex Health Innovation Forum: Southampton on May 16th 2017.
Advanced health technologies and their budgetary implications - Valérie Paris...OECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th meeting of the joint OECD DELSA-GOV network on fiscal sustainability of health systems held in Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Valerie Paris, OECDOECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
20191203 DOE Data Driven Healthcare- Expert EventDayOne
DayOne Experts - Data-driven healthcare – are we ready?
Data is transforming healthcare. Health data from multiple sources such as electronic health records, genomic testing, imaging and digital tools, combined with advanced analytics can be used to deliver more personalised care, improve outcomes, empower patients and make healthcare more sustainable and efficient. But is the industry ready for these new approaches? What is needed on the policy level and in the regulatory field to enable a new era of data driven health solutions? How will their business models look like?
This is what we discussed at this DayOne Expert Event, which was proudly presented in close collaboration with the Embassy of the Netherlands, fostering the exchange between two world leading healthcare innovation ecosystems.
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
-The Complexities, Challenges and Opportunities of New Zealand’s Health System.
- The Role of Care Coordination.
- DXC Health in New Zealand.
- DXC’s Care Coordination.
- Health Data Analytics.
- Interactive Session.
Presented by:
- Karen Blake, Regional Manager Health Information, Blake Consulting.
- Simon Kingston, Country Manager NZ, DXC Eclipse.
- Antony Zigliani, Practice Manager - BI/Analytics, DXC Eclipse.
Consumerism, Innovation and Best Practices to Thrive in the Future of HealthJustin Barnes
May 1, 2019 University of Toronto, Dalla Lana School of Public Health, The Institute of Health Policy, Management and Evaluation (IHPME) Keynote speaker Justin Barnes, a health innovation strategist and co-founder of Health Innovation Think Tank, will provide yet another integral perspective focused on the ways in which we can scale up and implement evidence-based changes in health care technology on a global scale. Having testified before Congress on more than twenty occasions delivering statements on virtual care, alternative payment methods, consumerism, connected health and the globalization of healthcare, Justin offers thought leadership for the university, the healthcare community as well as other key stakeholders.
Consumer Driven Health – IHPME Research Day
Looks to the Future of Health Care
The trend towards consumer driven health, whether it be mobile apps, wearable devices, or easy access to electronic health records, is changing the landscape of our health care system and the way we think about care.
Augmented Personalized Health: using AI techniques on semantically integrated...Amit Sheth
Keynote @ 2018 AAAI Joint Workshop on Health Intelligence (W3PHIAI 2018), 2 February 2018, New Orleans, LA [Video: https://youtu.be/GujvoWRa0O8]
Related article: https://ieeexplore.ieee.org/document/8355891/
Abstract
Healthcare as we know it is in the process of going through a massive change - from episodic to continuous, from disease-focused to wellness and quality of life focused, from clinic centric to anywhere a patient is, from clinician controlled to patient empowered, and from being driven by limited data to 360-degree, multimodal personal-public-population physical-cyber-social big data-driven. While the ability to create and capture data is already here, the upcoming innovations will be in converting this big data into smart data through contextual and personalized processing such that patients and clinicians can make better decisions and take timely actions for augmented personalized health. In this talk, we will discuss how use of AI techniques on semantically integrated patient-generated health data (PGHD), environmental data, clinical data, and public social data is exploited to achieve a range of augmented health management strategies that include self-monitoring, self-appraisal, self-management, intervention, and Disease Progression Tracking and Prediction. We will review examples and outcomes from a number of applications, some involving patient evaluations, including asthma in children, bariatric surgery/obesity, mental health/depression, that are part of the Kno.e.sis kHealth personalized digital health initiative.
Background: Background: http://bit.ly/k-APH, http://bit.ly/kAsthma, http://j.mp/PARCtalk
Chris Hollis - Big Data in Mental Health - 23rd July 2014 - 1kclcompbio
Organised by the Bioinformatics group at the BRCMH, IoP, SLaM and Maudsley Digital, this symposium showcased talks regarding the important roles of big data in mental health biomedical research and treatments.
Presentation by Terry Whalley, Director of Delivery, Cheshire & Merseyside Health & Care Partnership at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Ed Millensted - Innovation Scouts: Collaboration and learningInnovation Agency
Presentation by Ed Millensted, Programme Manager, Innovation Agency at the Innovation Scouts: Collaboration and learning event on Thursday, 10 October at The Royal College of Physicians, Liverpool.
EuroBioForum 2013 - Day 1 | Pierre MeulienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Genomics and personalised health in Canada
Dr Pierre Meulien, President and CEO at Genome Canada
=======================================
http://www.eurobioforum.eu
Precision and Participatory Medicine - Medinfo 2015 Panel on big data. Includes the proposal to use the term Expotype to characterise the Exposome of an individual. Electronic expo typing would refer to the automatic construction of individual expo types from electronic clinical records and other sources of environmental risk factor and exposure data.
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
More Related Content
Similar to Excel in Health Series - Introduction to Data
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
-The Complexities, Challenges and Opportunities of New Zealand’s Health System.
- The Role of Care Coordination.
- DXC Health in New Zealand.
- DXC’s Care Coordination.
- Health Data Analytics.
- Interactive Session.
Presented by:
- Karen Blake, Regional Manager Health Information, Blake Consulting.
- Simon Kingston, Country Manager NZ, DXC Eclipse.
- Antony Zigliani, Practice Manager - BI/Analytics, DXC Eclipse.
Consumerism, Innovation and Best Practices to Thrive in the Future of HealthJustin Barnes
May 1, 2019 University of Toronto, Dalla Lana School of Public Health, The Institute of Health Policy, Management and Evaluation (IHPME) Keynote speaker Justin Barnes, a health innovation strategist and co-founder of Health Innovation Think Tank, will provide yet another integral perspective focused on the ways in which we can scale up and implement evidence-based changes in health care technology on a global scale. Having testified before Congress on more than twenty occasions delivering statements on virtual care, alternative payment methods, consumerism, connected health and the globalization of healthcare, Justin offers thought leadership for the university, the healthcare community as well as other key stakeholders.
Consumer Driven Health – IHPME Research Day
Looks to the Future of Health Care
The trend towards consumer driven health, whether it be mobile apps, wearable devices, or easy access to electronic health records, is changing the landscape of our health care system and the way we think about care.
Augmented Personalized Health: using AI techniques on semantically integrated...Amit Sheth
Keynote @ 2018 AAAI Joint Workshop on Health Intelligence (W3PHIAI 2018), 2 February 2018, New Orleans, LA [Video: https://youtu.be/GujvoWRa0O8]
Related article: https://ieeexplore.ieee.org/document/8355891/
Abstract
Healthcare as we know it is in the process of going through a massive change - from episodic to continuous, from disease-focused to wellness and quality of life focused, from clinic centric to anywhere a patient is, from clinician controlled to patient empowered, and from being driven by limited data to 360-degree, multimodal personal-public-population physical-cyber-social big data-driven. While the ability to create and capture data is already here, the upcoming innovations will be in converting this big data into smart data through contextual and personalized processing such that patients and clinicians can make better decisions and take timely actions for augmented personalized health. In this talk, we will discuss how use of AI techniques on semantically integrated patient-generated health data (PGHD), environmental data, clinical data, and public social data is exploited to achieve a range of augmented health management strategies that include self-monitoring, self-appraisal, self-management, intervention, and Disease Progression Tracking and Prediction. We will review examples and outcomes from a number of applications, some involving patient evaluations, including asthma in children, bariatric surgery/obesity, mental health/depression, that are part of the Kno.e.sis kHealth personalized digital health initiative.
Background: Background: http://bit.ly/k-APH, http://bit.ly/kAsthma, http://j.mp/PARCtalk
Chris Hollis - Big Data in Mental Health - 23rd July 2014 - 1kclcompbio
Organised by the Bioinformatics group at the BRCMH, IoP, SLaM and Maudsley Digital, this symposium showcased talks regarding the important roles of big data in mental health biomedical research and treatments.
Presentation by Terry Whalley, Director of Delivery, Cheshire & Merseyside Health & Care Partnership at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Ed Millensted - Innovation Scouts: Collaboration and learningInnovation Agency
Presentation by Ed Millensted, Programme Manager, Innovation Agency at the Innovation Scouts: Collaboration and learning event on Thursday, 10 October at The Royal College of Physicians, Liverpool.
EuroBioForum 2013 - Day 1 | Pierre MeulienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Genomics and personalised health in Canada
Dr Pierre Meulien, President and CEO at Genome Canada
=======================================
http://www.eurobioforum.eu
Precision and Participatory Medicine - Medinfo 2015 Panel on big data. Includes the proposal to use the term Expotype to characterise the Exposome of an individual. Electronic expo typing would refer to the automatic construction of individual expo types from electronic clinical records and other sources of environmental risk factor and exposure data.
Similar to Excel in Health Series - Introduction to Data (20)
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
Supporting the optimal detection and management of BP in Primary CareInnovation Agency
Presentation by Jane Briers, Programme Manager - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Dr Lauren Moorcroft, GP Partner - Brookvale Practice at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Introduction to Supporting recovery in Primary Care using Proactive Framework...Innovation Agency
Presentation by Julia Reynolds, Associate Director for Transformation - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentations by Mike Kenny, Acting Co-Director of Enterprise and Growth, Innovation Agency and Dr Neil Paul, a GP and Board Member with Cheshire East ICP at the Excel in Health: Understanding the NHS Landscape webinar on Wednesday 11 May 2022.
LCR and Cheshire and Merseyside Health MATTERS networking eventInnovation Agency
Master slide deck from the LCR and Cheshire and Merseyside Health MATTERS networking event on Wednesday 24 November 2021 at Sci-Tech Daresbury Laboratory.
Master slide deck from the Excel in Health webinar series: The NHS landscape presentation.
This webinar identifies the structure of the NHS and its national priorities.
The session will cover the following topics:
Understand the structure of the NHS
Understand the national priorities of the NHS
Recognise the barriers to sale
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
9. 42 ICBs (and ICSs)
Cheshire & Merseyside Health & Care Partnership
Healthier Lancashire & South Cumbria
Local Priorities
Workforce
Population health
System integration
14. Estimated 11.8 million
adults (16+) in England had
hypertension in 2017
Hypertension is a major risk
factor for heart disease,
stroke and kidney disease
16. Greener NHS
net zero by 2045, with an
ambition to reach an 80%
reduction by 2036 to
2039.
-500
0
500
1000
1500
2000
2500
3000
GHG Trajectory
Scope 1 Scope 2 Scope 3 Target Linear (Target)
17. age
gender reassignment
being married or in a civil
partnership
being pregnant or on maternity
leave
disability
race including colour, nationality,
ethnic or national origin
religion or belief
sex
Urban / rural
Digital exclusion
Care / prison leavers
Homelessness
18.
19. Disclaimer
• Uptake and implementation of innovation
and national policy guidelines
• Commissioning support
• Patient pathway analysis
• Benchmarking
• Disease burden analytics
• Business cases
• Epidemiology research
• Health economic research
• Quality and Outcomes analysis
• Sales or marketing purposes
• to healthcare professionals
• Sales brochures
• Emails
• Presentations
• Direct mailing
• Advertising of pharmaceutical products or
medical technology.
Internal Use Only
20. Justify the purpose(s) for using
confidential information
Use confidential information
only when it is necessary
Use the minimum necessary
confidential information
Access to confidential
information should be on a
strict need-to-know basis
Everyone with access to
confidential information should
be aware of their
responsibilities
Comply with the law
The duty to share information
for individual care is as
important as the duty to protect
patient confidentiality
Inform patients and service
users about how their
confidential information is used
21. ICD 10 - International Classification of Diseases
SNOMED CT (Systematised Nomenclature of Medicine -
Clinical Terms)
22.
23.
24. Paul Brain – Enterprise and Growth
Paul.Brain@innovationagencynwc.nhs.uk
@PaulEBrain
Introduction to Data
Editor's Notes
Lots of ways to do ‘desk research’ online and for free before paying for market research or beginning face to face validation (save yourself time, pain and money):
For a bigger picture:
NHSX –New Digital Unit Leading on NHS Digital Strategy, becoming the NHS Transformation Directorate
The NHS RightCare works collaboratively with systems to look at nationally collected, robust data to identify opportunities and potential threats
The website has CCG and STP data packs plus The Atlas of Variation (interactive map produced by public health England showing population health metrics such as end of life care)
NHS Efficiency Map; Online tool from Healthcare financial management association.
The map is a tool that promotes best practice in identifying, delivering and monitoring cost improvement programmes (CIPs) and quality, innovation, production and prevention (QIPP) schemes in the NHS. The map contains links to a range of tools and guidance to help NHS bodies improve their efficiency. Golden ticket is if you develop an offering that aligns to a cost improvement programme (CIP) and offers incremental value over the current options
Public Health Dashboards:
Search on Public Health indicators (smoking, obesity etc) to understand burden of disease and local variance.
Get It Right First Time:
National programme designed to improve the quality of care within the NHS by reducing unwarranted variations. It’s a showcase of best practice with the aim of improving efficiencies.
Local Priorities
Strategic Plan: Core Strategic aims plus detail on specific trust /CCG challenges in the Healthcare Needs analysis section.
JSNA: Joint Strategic Needs Assessment – local authority / public health produced reports based on local populations
Often have a ‘plan on a page’ or a summary infographic that makes life easy when you are trying to understand how they think.
Annual reports: You’ll get an overview of achievement within the year, financial achievements and risk plus governance info. (provider and CCG)
Quality Accounts: Published by providers annually. You can find performance against national standards, detail on further improvements they need to make, performance against NHS National Outcome Indicators and ‘never events (serious, largely preventable incidents)
Understanding current practice:
Guidelines: Help you to find out current best practice across the specific patient pathway you wish to augment or disrupt.
Understanding the competition:
National Primary Care prescribing data: On NHS Digital website. Spend per practice on medicines/ dressing etc. Useful if you a preventing patients from going on to need drugs/ minor surgery etc and want to understand the demand an cost implications
Systematic Literature review: Essential to help you understand the competition and/ or what the current standard of care is. You won’t be selling in a vacuum, so understand what your comparator is and the ‘incremental’ value you add. If you don’t find any competition and the current standard of care is ‘do nothing’ then you still need to understand the implications of that.
NHS Evidence: Search on NICE guidance, BNF and research
Once you have an idea of need from desk research, validate it with real people;
Procurement: Great way to understand if your suspected need is a real challenge and if your perceived value meets their expectations/ drivers for change. (Already had a sesson from Rachel from SBS)
Relevant professionals: eg clinicians in your particular field, digital leads, service or transformation managers. Don’t forget about clinical engagement –it’s very important to determine the real need and patient benefit …even though it might not be them purchasing your solution directly, don’t under estimate the power of a clinical advocate.